The reimbursement process in three national healthcare systems: variation in time to reimbursement of pembrolizumab for metastatic non-small cell lung cancer.

Sharman Moser, Sarah; Tanser, Frank; Siegelmann-Danieli, Nava; Apter, Lior; Chodick, Gabriel; Solomon, Josie

Sharman Moser, Sarah; Tanser, Frank; Siegelmann-Danieli, Nava; Apter, Lior; Chodick, Gabriel; Solomon, Josie.

Sharman Moser S; Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, 27 Hamered St, 6812509, Tel Aviv, Israel. moser_sa@mac.org.il.
Tanser F; Lincoln International Institute of Rural Health, Lincoln Medical School, University of Lincoln, Brayford Way, Brayford Pool, Lincoln, LN6 7TS, UK.
Siegelmann-Danieli N; Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, 27 Hamered St, 6812509, Tel Aviv, Israel.
Apter L; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Chodick G; Maccabi Institute for Research and Innovation (Maccabitech), Maccabi Healthcare Services, 27 Hamered St, 6812509, Tel Aviv, Israel.
Solomon J; Department of Health Systems Management, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

J Pharm Policy Pract ; 16(1): 22, 2023 Feb 16.

Article en En | MEDLINE | ID: mdl-36797806